<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227032</url>
  </required_header>
  <id_info>
    <org_study_id>LCCC 0424</org_study_id>
    <secondary_id>CDR0000550155</secondary_id>
    <nct_id>NCT00227032</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme</brief_title>
  <official_title>Phase I Study of Erlotinib Administered Every 72 Hours in Patients With Glioblastoma Multiforme With Pharmacokinetic/Pharmacodynamic Correlates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNC Lineberger Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UNC Lineberger Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in&#xD;
      treating patients with progressive glioblastoma multiforme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of erlotinib hydrochloride when administered in&#xD;
           escalating doses every 72 hours in patients with progressive glioblastoma multiforme.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the relationship between plasma and cerebrospinal fluid (CSF) concentrations&#xD;
           of erlotinib hydrochloride in these patients.&#xD;
&#xD;
        -  Determine the relationship between plasma and CSF concentrations of erlotinib&#xD;
           hydrochloride in patients not receiving concurrent enzyme-inducing antiepileptic drugs&#xD;
           (EIAEDs) vs those receiving concurrent EIAEDs.&#xD;
&#xD;
        -  Correlate CYP3A4 activity, as measured by midazolam hydrochloride clearance, with plasma&#xD;
           clearance of erlotinib hydrochloride in these patients.&#xD;
&#xD;
        -  Correlate CYP1A2 activity, as measured by the 4-hour paraxanthine (17X)/caffeine (137X)&#xD;
           plasma ratio, with plasma clearance of erlotinib hydrochloride in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, objective response and disease progression in patients treated&#xD;
           with erlotinib hydrochloride.&#xD;
&#xD;
        -  Correlate the presence of EGFRvIII mutation with objective response and disease&#xD;
           progression in patients treated with erlotinib hydrochloride.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study. Patients are stratified according to&#xD;
      use of concurrent enzyme-inducing antiepileptic drugs (EIAEDs) (yes vs no).&#xD;
&#xD;
      Patients receive oral erlotinib hydrochloride once every 72 hours for 28 days. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses* of erlotinib hydrochloride until the&#xD;
      maximum tolerated dose (MTD) is determined or preliminary results show no direct relationship&#xD;
      between plasma and cerebrospinal fluid concentrations. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      NOTE: *Interim enrollment of patients is allowed; these patients receive the current approved&#xD;
      dose of erlotinib hydrochloride.&#xD;
&#xD;
      Patients undergo blood sample collection periodically on day 13 for pharmacokinetic studies.&#xD;
      The pharmacokinetic study comprises midazolam hydrochloride and caffeine clearance assessment&#xD;
      and correlation of these assessments with CYP3A4 activity and CYP1A2 activity.&#xD;
&#xD;
      Paraffin-embedded and frozen tumor tissue is obtained from patients who underwent prior&#xD;
      surgical resection for analysis of wild-type EGFR and EGFRvIII mutation by&#xD;
      immunohistochemistry.&#xD;
&#xD;
      Quality of life is assessed at baseline and then at 1 month and 6 months.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Loss of funding&#xD;
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Progression -free survival will be measured by radographic response using RECIST critera.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between presence of the EGFRvIII mutation with treatment outcomes</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Subjects receiving EIAEDs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects NOT taking EIAEDs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>300 mg, per day for subjects taking EIAEDs&#xD;
150 mg, per day for those NOT taking EIAEDs</description>
    <arm_group_label>Subjects NOT taking EIAEDs</arm_group_label>
    <arm_group_label>Subjects receiving EIAEDs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed glioblastoma multiforme (or high-grade glioma that is&#xD;
             behaving clinically and/or radiographically like glioblastoma multiforme)&#xD;
&#xD;
          -  Progressed after first-line therapy (e.g., surgery, chemotherapy, or radiotherapy)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  ANC &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 8.5 g/dL&#xD;
&#xD;
          -  ALT and AST &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2 times ULN&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No diagnosis or history of significant renal or hepatic disease&#xD;
&#xD;
          -  No contraindication (e.g., mass effect, brain shift) to lumbar puncture procedure&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No diagnosis or history of corneal abnormalities&#xD;
&#xD;
          -  No diagnosis or history of malabsorptive syndrome or other disorder affecting&#xD;
             gastrointestinal absorption&#xD;
&#xD;
          -  No history of hypersensitivity reactions to midazolam hydrochloride (CYP3A4 biomarker)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celeste Lindley, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frances A. Collichio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Lineberger Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

